University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
J

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benefit to Ruxolitinib for Patients With CSF3R Mutation?

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jeffrey Tyner
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Jeffrey Tyner
40 views
October 27, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

15:43
Incyte

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey
CML and MPNs: Final Frontiers and New Breakthroughs
21:24

2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benefit t…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Tyner

40 views
26:24

2020 Update on CML: What Strategies Can Help Overcome Multi-TKI Resi…

University of Miami's 2nd Biennial Miami Leukemia Symposium

J. Cortés

153 views
25:18

2020 Update on Ph- MPN: What Are the Potential Benefits and Limitati…

University of Miami's 2nd Biennial Miami Leukemia Symposium

O. Odenike

166 views
21:19

2020 Update on BPDCN: Efficacy Analysis of Available Standard Therap…

University of Miami's 2nd Biennial Miami Leukemia Symposium

N. Pemmaraju

19 views